CTLA4 and breast carcinoma: To assess the impact of VISTA expression on the establishment of an immunosuppressive microenvironment in breast cancer, a comparison was made with the main inhibitory immune checkpoints used in immunotherapy, namely PD-1, PDL-1 and CTLA-4.